Latest studies
- RecruitingPHASE2
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
This study is testing a new medicine, BI 3034701, to see if it helps adults with obesity or overweight lose weight. Participants will get either the medicine or dummy medicine, plus advice on diet and exercise.
ObesityOverweightNew Zealand - Active not recruitingPHASE2
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This study looks at giving olaparib, a new drug, before surgery and chemotherapy for recurrent ovarian, primary peritoneal, or fallopian tube cancer. It aims to see if it can shrink tumours and improve outcomes.
Ovarian CancerFallopian Tube CancerNeoadjuvant TreatmentDebulking Surgical ProceduresNew Zealand - RecruitingPHASE3
Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
This study looks at a new medicine, VMX-C001, for people taking blood thinners (FXa DOACs) who need urgent surgery. The goal is to see if VMX-C001 helps stop bleeding effectively during the operation compared to usual care. Experts will check how well bleeding is controlled.
Blood Loss, SurgicalCoagulation DisorderNew Zealand - Recruiting
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
This study looks at issues that can happen when breathing tubes are removed after surgery or critical illness. Researchers want to understand why these problems happen and how medical teams can improve this common procedure to make it safer for everyone.
ExtubationNew Zealand - Active not recruitingPHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
This study looks at a new combination of medicines for postmenopausal women with a certain type of breast cancer. It tests if abemaciclib with standard hormone therapy works better than hormone therapy alone.
Breast CancerNew Zealand - RecruitingPHASE2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
This study is testing a new medicine, Vamifeport, for people with a common type of iron overload called hereditary hemochromatosis. It aims to see if the medicine can reduce the amount of iron stored in the liver. Two groups will be compared: one getting the medicine and one getting a dummy pill.
Homeostatic Iron Regulator Gene-related Hereditary HemochromatosisNew Zealand - RecruitingPHASE3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This study is testing a new combination of two medicines, calderasib and pembrolizumab, for a specific type of lung cancer. We want to see if this combination works better than current treatments for people with advanced non-small cell lung cancer that has a particular genetic change.
Non-small Cell Lung CancerNew Zealand - Active not recruitingPHASE3
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is looking at a new medicine called acalabrutinib for chronic lymphocytic leukaemia (CLL). It compares acalabrutinib to usual treatments to see which works best for people whose CLL has come back or hasn't responded to previous treatment.
Chronic Lymphocytic LeukemiaNew Zealand - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseNew Zealand - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseNew Zealand - Active not recruitingPHASE3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This study looks at a new drug, bomedemstat, for essential thrombocythemia (ET). It compares bomedemstat to standard treatments for people whose current medicine, hydroxyurea, isn't working well or causes too many side effects. We want to see if bomedemstat is safer and works better.
Essential ThrombocythemiaNew Zealand - RecruitingPHASE1, PHASE2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
This study is testing new treatments, alone or in combination, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if these treatments are safe and effective in helping men with this condition.
Castration-Resistant Prostatic CancerMetastasisNew Zealand - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
This study looks at new treatments, sacituzumab tirumotecan alone or with pembrolizumab, for triple-negative breast cancer. It compares their effectiveness with standard chemotherapy to see if they help people live longer or stop cancer growth.
Triple Negative Breast NeoplasmsNew Zealand - RecruitingPHASE3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study is looking into a new drug, PF-06821497, combined with an existing drug, enzalutamide, for men with advanced prostate cancer. It wants to see if this combination works better than enzalutamide alone for those who haven't had certain other treatments.
Metastatic Castration-Resistant Prostate CancerNew Zealand - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisNew Zealand - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
DLBCLDiffuse Large B-Cell LymphomaNew Zealand - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaNew Zealand - RecruitingPHASE3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study looks at a new medicine called survodutide for adults with a liver condition called NASH or MASH and scarring (cirrhosis). Participants will get either the medicine or a dummy treatment, along with diet and exercise advice, to see if it helps their liver.
Metabolic Dysfunction Associated SteatohepatitisNew Zealand - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
This study is comparing two treatments, belzutifan plus pembrolizumab, against pembrolizumab alone, for kidney cancer that has been removed. It aims to see if the combination treatment can prevent the cancer from returning.
Carcinoma, Renal CellNew Zealand - RecruitingPHASE3
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
This study for advanced neuroendocrine cancer compares a new drug called obrixtamig with standard chemotherapy. It aims to see if adding obrixtamig helps people live longer and also tests a new device to measure a cancer marker.
Extrapulmonary Neuroendocrine Cancer (epNEC)New Zealand - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisNew Zealand - Active not recruitingPHASE3
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
This study is comparing two medicines, milvexian and apixaban, for people with an irregular heartbeat called atrial fibrillation. We want to see if milvexian is just as good as apixaban at stopping serious problems like strokes, which can happen with this condition.
Atrial FibrillationNew Zealand - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This study is testing a new combination of medicines, Giredestrant and Palbociclib, for advanced breast cancer. It's for people whose cancer is hormone-sensitive (ER-positive) but not HER2-positive. Researchers want to see if this new combination works better and is safer than a standard treatment.
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerNew Zealand - RecruitingPHASE3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study compares a new medicine, pirtobrutinib, with ibrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's for adults, some of whom may have had previous treatment, and some who are newly diagnosed, especially if they have a specific gene change.
Chronic Lymphocytic LeukemiaLeukemia, LymphocyticLeukemia, B-cellSmall Lymphocytic LymphomaNew Zealand - RecruitingPHASE2, PHASE3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
This study is looking at a new oral medicine, enlicitide decanoate, for children and teenagers aged 6-17 with a condition called Heterozygous Familial Hypercholesterolemia (HeFH). We want to see if it's safe and helps lower high cholesterol levels.
Heterozygous Familial Hypercholesterolemia (HeFH)New Zealand - RecruitingPHASE3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
This study is looking at a new drug, casdatifan, combined with an existing one, cabozantinib, for advanced clear cell kidney cancer. It compares this combination to cabozantinib with a dummy drug (placebo) to see if it stops cancer growth for longer in patients who've already had immunotherapy.
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaNew Zealand - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
This study is looking into a new treatment called Dazodalibep for Sjögren's Syndrome. It wants to see if the treatment helps reduce symptoms and if it's safe for people whose Sjögren's is causing moderate to severe problems in their body.
Sjogren's SyndromeNew Zealand - RecruitingPHASE2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
This study is testing a new medicine, PIPE-791, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). We want to see how well it works, if it's safe, and if people can tolerate it. It's a phase 2 study, meaning we're still in the early stages of testing.
Idiopathic Pulmonary FibrosisNew Zealand - RecruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
Chronic Lymphocytic LeukemiaNew Zealand - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerNew Zealand - RecruitingPHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study is looking at a new treatment for non-small cell lung cancer after surgery. It combines two medicines, sacituzumab tirumotecan and pembrolizumab, to see if they work better together than pembrolizumab alone in preventing the cancer from coming back.
Non Small Cell Lung CancerNew Zealand - RecruitingPHASE3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study looks at a new drug, mevrometostat, combined with enzalutamide for men with prostate cancer that has spread. It compares this combination to enzalutamide alone, to see if it works better for those not yet treated with specific hormone therapies.
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate CancerCancer of the ProstateNew Zealand - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseNew Zealand - RecruitingPHASE2, PHASE3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
This study looks at a new drug, ficerafusp alfa, combined with pembrolizumab (Keytruda®) for people with advanced head and neck cancer. It compares this combination against pembrolizumab alone to see if it works better and is safe.
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaNew Zealand - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionNew Zealand - RecruitingPHASE3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study looks at a new medicine called survodutide for adults with a liver condition called MASH and moderate to advanced liver damage. It aims to see if the medicine can improve liver health and how safe it is.
Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver FibrosisNew Zealand - RecruitingPHASE2, PHASE3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
This study is looking at a new medicine called vericiguat for children and young people aged 29 days to 17 years with heart failure. We want to see if it can improve their heart health compared to a dummy medicine.
Heart FailureLeft Ventricular Systolic DysfunctionNew Zealand - RecruitingPHASE3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.
Idiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisNew Zealand - Active not recruitingPHASE3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
This study looks at whether a new medicine, retatrutide, can help adults with obesity who also have heart disease or kidney problems. It aims to see if the medicine can reduce serious heart issues or stop kidney problems from getting worse.
Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)New Zealand - RecruitingPHASE3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
This study compares two treatments for newly diagnosed multiple myeloma in adults who can't have a stem cell transplant. It aims to see if a combination including Elranatamab is better than another standard combination at controlling the cancer and improving patients' lives.
Multiple MyelomaNew Zealand - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsNew Zealand - Active not recruitingPHASE3
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, apalutamide, for men with prostate cancer that hasn't spread but is resistant to standard treatment. It aims to see if the drug can stop the cancer from spreading and if it's safe to use.
Prostatic NeoplasmsNew Zealand - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisNew Zealand - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesNew Zealand - RecruitingPHASE2
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
This study looks into a new medicine called IPN10200, given as injections, to see if it can prevent migraine headaches in adults. It will check if the treatment is safe and how well it works for people who get migraines often.
Episodic MigraineChronic MigraineNew Zealand - Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
This study looks at how well a medicine called risankizumab works and how safe it is for people with ulcerative colitis. It's for those who have already shown improvement with this medicine in a previous study.
Ulcerative Colitis (UC)New Zealand - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNew Zealand - Active not recruitingPHASE3
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This study looks at a new daily pill, enlicitide decanoate, for people at high risk of heart problems like heart attacks or strokes. It aims to see if this pill can help reduce these serious events safely, compared to a dummy pill.
ArteriosclerosisHypercholesterolaemiaNew Zealand - RecruitingPHASE3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
This study is looking into the long-term safety of a new medicine called dazodalibep for people with Sjögren's Syndrome. It involves individuals who have already taken part in previous studies of this medicine.
Sjögren's SyndromeNew Zealand - Active not recruitingPHASE2
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
This study is testing a new inhaled medicine, RCT2100, for cystic fibrosis. It will first check if it's safe for healthy people, then for people with CF, sometimes alongside other CF treatments. We aim to understand its safety and how the body handles it.
Cystic FibrosisNew Zealand